A New Way To Tackle Deal Valuations: Infectious Disease As A Case Study
Despite regulatory uncertainty, the growing problem of antibiotic resistance – especially for gram-negative organisms – has forced big drug companies to take renewed interest in novel anti-infectives.
You may also be interested in...
Deal enables biotech to monetize a portion of its ribosome research while maintaining control over larger segments.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.